Loading
HP518 is an experimental oral PROTAC protein degrader from Hinova Pharmaceuticals, in phase 2 trials for metastatic castration-resistant prostate cancer.
HP518 is an oral PROTAC protein degrader from Hinova Pharmaceuticals. An oral degrader that removes both the normal androgen receptor and receptor variants resistant to enzalutamide. Its furthest stage is phase 2, for metastatic castration-resistant prostate cancer. ClinicalTrials.gov registers it in 2 studies linked below. Hinova: 'At present HP518 is in Phase I/II clinical study'. NCT06155084 phase 1/2 recruiting; Australian phase 1 NCT05252364 completed. Whether it works in people has not been established unless a trial below reports it.
An oral degrader that removes both the normal androgen receptor and receptor variants resistant to enzalutamide. Connects to Androgen receptor.
1.HP518 binds Androgen receptor with one end and an E3 ubiquitin ligase with the other.
Background: ADC sequencing, Antigen escape (antigen loss, lineage switch), BCG-unresponsive, Castration-resistant prostate cancer (CRPC), Circulating tumour DNA (ctDNA). Also on OnCo: Resistance: how tumours escape each drug class · Lines of therapy.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"HP518" OR ABSTRACT:"HP518") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about HP518, not a curated reading list.
Shares Hinova Pharmaceuticals, Metastatic castration-resistant prostate cancer and the tag pipeline.
Shares Hinova Pharmaceuticals, Metastatic castration-resistant prostate cancer and the tag pipeline.
Shares Hinova Pharmaceuticals, Metastatic castration-resistant prostate cancer and the tag pipeline.
Shares Hinova Pharmaceuticals, Metastatic castration-resistant prostate cancer and the tag pipeline.
Shares Hinova Pharmaceuticals, Metastatic castration-resistant prostate cancer and the tag pipeline.
Shares Hinova Pharmaceuticals, Androgen receptor, Metastatic castration-resistant prostate cancer and the tag pipeline.
Shares Androgen receptor, Metastatic castration-resistant prostate cancer and the tag pipeline.
Shares Metastatic castration-resistant prostate cancer and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/